|

sCD163 in PBC Patients - Assessment of Treatment Response

RECRUITINGSponsored by University of Aarhus
Actively Recruiting
SponsorUniversity of Aarhus
Started2016-09
Est. completion2031-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT02931513

Summary

Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR can predict response to treatment with UDCA in newly diagnosed patients with PBC.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Newly diagnosed with Primary biliary cholangitis
* No treatment with UDCA

Exclusion Criteria:

* Patient under 18 years
* Expected lifetime under 6 months
* Expected liver transplantation within 6 months
* Liver cancer
* Cirrhosis from other causes

Conditions4

Liver DiseaseLiver InflammationPrimary Biliary CirrhosisUrsodeoxycholic Acid

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.